Durability and Depth of Response With BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Dr. Hans Lee and Dr. Jing Christine Ye discuss the evolution of clinical data for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma, focusing on the increasing understanding of response depth and durability with longer follow-up. Dr. Lee highlights the initially impressive response rates observed with these off-the-shelf therapies and asks Dr. Ye to interpret the longer-term findings from the LINKER-MM1 study. Dr. Ye discusses the 21-month follow-up data and emphasizes the importance of evaluating both the depth and duration of response when assessing treatment activity. She notes the reported duration of response of approximately 29.4 months and highlights the relevance of outcomes observed across subgroups, including patients with high-risk cytogenetics and high disease burden. Dr. Lee reinforces the significance of durable responses in clinical practice, describing his experience with patients receiving linvoseltamab and noting that patients who respond well may maintain their responses even with reduced dosing frequency.